RedHill Biopharma Ltd.
RDHL
$1.02
-$0.01-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 2.04M | 2.04M | 2.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 2.04M | 2.04M | 2.74M |
| Cost of Revenue | -- | -- | 803.50K | 803.50K | -- |
| Gross Profit | -- | -- | 1.24M | 1.24M | -- |
| SG&A Expenses | -- | -- | 2.94M | 2.94M | -7.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 4.23M | 4.23M | -9.18M |
| Operating Income | -- | -- | -2.19M | -2.19M | 3.88M |
| Income Before Tax | -- | -- | -2.07M | -2.07M | 6.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -2.07M | -2.07M | 6.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -2.07M | -2.07M | -2.59M |
| EBIT | -- | -- | -2.19M | -2.19M | 3.88M |
| EBITDA | -- | -- | -2.11M | -2.11M | 3.72M |
| EPS Basic | -11.46K | -11.46K | -11.46K | -11.46K | -20.31K |
| Normalized Basic EPS | -- | -- | -0.72 | -0.72 | 2.50 |
| EPS Diluted | -11.46K | -11.46K | -11.46K | -11.46K | -20.31K |
| Normalized Diluted EPS | -- | -- | -0.72 | -0.72 | 2.50 |
| Average Basic Shares Outstanding | 3.16M | -- | 1.80M | 1.80M | 1.23M |
| Average Diluted Shares Outstanding | 300.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |